Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma

NCT00961467 is registered in ClinicalTrials.gov with Fondazione EMN Italy Onlus as lead sponsor.

NCT NCT00961467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00961467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide, Melphalan, Prednisone, and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma
Lead sponsor
Fondazione EMN Italy Onlus
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
April 30, 2016
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma